Antibody-binding structures (B-cell epitopes) of several antigens from the asexual blood stages of the malaria parasite Plasmodium falciparum have recently been identified as potential vaccine candidates for the control of morbidity and mortality of this disease (1) . However, in spite of the fact that both antibody-dependent and antibody-independent immune protection to the malaria parasite are controlled by T cells (2) , nothing is known of T-cell-activating structures (T-cell epitopes) in these blood stage antigens, a knowledge crucial for the design of efficient subunit vaccines (3) .
An antigen generally considered a major candidate for a merozoite vaccine is Pf155/RESA (4) (5) (6) . This antigen contains two extensive blocks of tandemly repeated amino acid sequences. The major units in its C-terminal block of repeats are the sequence Glu-Glu-Asn-Val-Glu-His-Asp-Ala, tandemly repeated five times, and the first half of this sequence (Glu-Glu-Asn-Val), repeated >30 times, including a few variants and deletions (7) . A major proportion of the human anti-Pf155 antibodies, which also efficiently inhibit erythrocyte invasion by merozoites in vitro, is directed against linear epitopes formed by these sequences (8, 9) , which also appear to be conserved between different P. falciparum strains (7, 10) .
We have earlier shown that intact Pf155 induces in vitro proliferation, interleukin 2 release, and interferon-y (IFN-y) production in T cells primed to this antigen by natural infection (11, 12) . In Pfl55-seropositive donors, the antigen has also been found to induce production of T-cell-dependent anti-Pf155 antibodies in vitro, suggesting that it possesses T-helper cell stimulating epitopes (13) . To define T-cellactivating regions for possible inclusion in a subunit vaccine, we have now investigated in vitro responses of T cells from donors with previous malaria experience to short synthetic peptides representing C-terminal repeats of Pf155/RESA. Structures Culture Conditions for Antigen-Induced T-Cell-Dependent B-Cell Activation. T cells supplemented with 5% autologous adherent cells were mixed with autologous B cells at a T-cell/B-cell ratio of 2:1. The cells, at a final concentration of 5 x 105 lymphocytes per ml, were suspended in tissue culture medium, supplemented with 10% heat-inactivated fetal bovine serum instead of human AB+ serum. Cultures containing adherent cells and either B or T cells were set up in parallel. The cell mixtures were put into round-bottomed tissue culture tubes (A/S, Nunc) in the presence or absence of antigen (10 ng/ml). After incubation for 4 days at 370C in humidified 95% air/5% C02, the medium was removed and fresh tissue culture medium without antigen was added. After further incubation for 12 days, the supernatants were harvested and stored at -20'C until analyzed for total immunoglobulin and anti-malaria antibodies.
Antigen Preparations. The P.falciparum antigen Pf155 was prepared by adsorbing spent P.falciparum culture medium to polyacrylamide beads conjugated with human glycophorine and subsequent elution with 3 M KSCN (17) . These preparations were highly enriched in Pfl55 but also contained some faster migrating (NaDodSO4/PAGE) but serologically crossreacting parasite components (ref. 17 ; K. Berzins, personal communication). Sonicates of schizont-enriched preparations were used as crude P. falciparum antigen and supernatants from sonicates of noninfected erythrocytes as control antigen (16) . Peptides were synthesized by solid-phase techniques, purified by HPLC, analyzed, and desalted as described (9) . The peptides used were >80% pure and nontoxic.
IFN-y Determination. For IFN-y estimation, supernatants were collected after 4 days of incubation when release was optimal. They were assayed undiluted in ELISA, with two distinct IFN-y-specific monoclonal antibodies used as catcher and indicator antibodies, respectively (18) . Human IFN-y (Gg 23-901-530, 4000 units per ampoule; National Institute of Allergy and Infectious Diseases, National Institutes of Health) was used as standard. The limits of sensitivity of the method were 2.5 units/ml and supernatants containing less than this were considered negative.
RESULTS AND DISCUSSION T-Cell-Dependent Antibody Production in Vitro. Using the previously described T-cell/B-cell cooperation system (13), we further investigated the T-cell-dependent production in vitro of anti-malaria antibodies in 30 donors, all primed to P. falciparum by natural infection. While T-cell stimulation with a crude P. falciparum antigen induced anti-parasite antibodies in 48% of the cultures, regardless of the donors' anti-PflS5 serum titers, antibodies to PflS5 were only induced in cultures from donors with anti-PflS5 titers .1:625 (6/19). Very similar results were obtained when cultures were stimulated with nanogram amounts of an antigen preparation highly enriched in PflS5. Induction of antibody production in vitro was strictly T-cell dependent and no anti-malaria antibodies were induced with control antigen. These results confirm and extend previous findings (13) , indicating that intact Pf1SS possesses T-helper cell stimulating epitopes.
Induction of DNA Synthesis (Proliferation Assay). To map
Pfl55 for T-cell-activating epitopes, synthetic peptides representing repeated sequences from its C terminus (7) were prepared and studied for their capacity to induce in vitro proliferation of T cells from P. falciparum primed donors. Fig. 1 shows the results of a typical experiment with T cells from four Liberian donors. Three donors (Fig. 1 a-c) responded well to an optimal dose of intact Pfl55, while one donor (Fig. ld) did not. Two of the donors (Fig. 1 a and b ) also responded positively (SI 2 2.5) in a dose-dependent manner but to different degrees to two slightly different peptides, each including several copies of the C-terminal repeat unit Glu-Glu-Asn-Val. These peptides were chosen because they were predicted to include dominant T-cell epitopes on the basis of high a-amphipathic scores when analyzed by the algorithm recently developed by Margalit et al. (19) . However, one of the donors also responded to a dimer of Glu-Glu-Asn-Val-Glu-His-Asp-Ala (Fig. ic) , which had a low a-amphipathic score. This donor did not respond to the Glu-Glu-Asn-Val repeat peptide p2a. The donor who did not 30 Immunology: Kabilan et (Fig. ld) .
Thus far, 96 donors (adult males) have been studied in detail. All were from an endemic P. falciparum area in Liberia (20) and were seropositive when tested for P. falciparum antibodies by conventional immunofluorescence. Moreover, -75% had anti-Pf155 titers (4) ranging from 1:50 to 1:25,000. In the T-cell-proliferation assay, there was no correlation between these serum titers and the magnitude of the lymphocyte response. In total, -50% of the donors responded positively to intact Pfl55. Table 1 (21) . On the other hand, only -65% of the Pf155 responders were stimulated above background by one or several of the peptides, suggesting the existence of additional T-cell-activating sites in the protein, sites not represented by any of the synthetic peptides used. Ongoing studies with a larger number of peptides suggest that such sites may exist preferentially in the second more N-terminally located repeat region of the molecule (M.T.-B., unpublished data). Table 2 shows some representative results of the stimulation assay in greater detail. It includes 10 malaria-primed Liberian donors and 7 Swedish controls not previously exposed to P. falciparum. In line with previous findings, (4) . Peptides used as stimulants were as follows: pla, Ala-Glu-Glu-Asn-Asp-Glu-Glu-Asn-Val-GluGlu-Val-(Glu-Glu-Asn-Val)2; p2a, Tyr-(Asn-Val-Glu-Glu)4-Cys; p3, Lys-(Glu-Glu-Asn-Val-Glu-His-Asp-Ala)2.
*[3H]Thymidine incorporation in absence of stimulant (background).
tStimulated with pib, Lys-Ala-(Glu-Glu-Asn-Val)2-Glu-Glu-Val-(Glu-Glu-Asn-Val)2.
fStimulated with p2b, Lys-(Glu-Glu-Asn-Val)4. For other explanations see Table 1. none of the controls responded to intact Pf155 (11, 12) or to any of the peptides representing three related sequences from its C-terminal repeat region. All Liberian donors included in this table responded above background (SI > 2.5) to intact Pf155. The responses seen were of a magnitude also found by others in similar investigations (22) . With the peptides, the strongest and most frequent responses were obtained with a 20-mer consisting essentially of 4 Glu-Glu-Asn-Val repeats surrounding the tripeptide Glu-Glu-Val (pla , Tables 1 and 2) . Equivalent results were obtained with a similar peptide differing from pla in only one position (pib, Table 1 ). Most but not all donors responding to these two peptides also responded to the peptide Tyr-(Asn-Val-Glu-Glu)4-Cys (p2a) or the related peptide Lys-(Glu-Glu-Asn-Val)4 (p2b). However, all donors responding to p2a (or p2b) always responded to pla (or pib). The minimal epitope involved in these reactions appears to comprise 3 Glu-Glu-Asn-Val units (data not shown). Many of the Pf155 responders also responded to p3, a dimer of the C-terminal 8-amino acid repeat unit Glu-Glu-Asn-Val-Glu-His-Asp-Ala of Pf155. However, in this case and in contrast to what was seen with p2a or p2b, Ninety-six Liberian donors were divided into PflS5 responders (SI 2 2.5) and Pfl55 nonresponders (SI < 2.5). SI values are means ± SEM from the total number of individuals tested with optimal concentrations of Pfl55 (0.5 ug/ml), peptide pl or peptide p3 (0.1 or 1 mM), erythrocyte control antigen (EO, 5 ,ug/ml) or T-cell mitogen (La, 10 ,g/ml). Significance of differences between SI (unpaired t test): PflS5, P < 0.0002; pl, P < 0.0005; p3, P < 0.004; EO and La, not significant.
tLys-(Glu-Glu-Asn-Val-Glu-His-Asp-Ala)2-Immunology: Kabilan et what extent they are cross-reactions. As the peptides have similar sequences, it is likely that they represent a few overlapping and cross-reacting epitopes. Current experiments with T-cell clones support this conclusion. However, the fact that some donors who responded poorly to the Glu-Glu-Asn-Val repeat peptides were significantly stimulated by the Glu-Glu-Asn-Val-Glu-His-Asp-Ala dimer suggest that the latter formed distinct non-cross-reacting epitopes seen by the T cells of only some PfUS5 responders. The important question is whether or not the different response patterns reflect differences in major histocompatibility complex restriction. Further experiments, utilizing a modified T-cell/B-cell cooperation system in vitro, are also needed to establish whether or not the epitopes defined in the proliferation assay are indeed T-helper cell activating sites, which induce B cells to produce PUS5-specific antibodies. It is noteworthy that some of the prevalent anti-PfUS5 antibodies in serum react with epitopes similar to those seen by the T cells discussed above (8, 9) . As IgG antibody formation to these epitopes depends on T-cell/B-cell cooperation (13) it may well require help by other T-cell-activating sites present on PfUS5 or on other parasite molecules (23) (24) (25) .
Induction of IFN-y Release. We have previously reported that stimulation in vitro of T cells from primed individuals with crude P. falciparum schizont antigens or PfUS5 induces release of IFN-y and that this may be indicative of the existence of an antibody-independent cellular immunity (11, 26) . No IFN-y release was induced in control donors' lymphocytes exposed to the same antigens. Similar results have recently been reported by others studying lymphocytes from Gambian adults (22) . In the present investigation, 31 of the Liberian donors were studied in detail for IFN-y release after in vitro stimulation with intact PfUS5 or synthetic peptides. The 31 donors were chosen because their T cells released significant amounts of IFN-y (31.7 ± 14.6 units/ml; mean ± SD) when stimulated with the T-cell mitogen La (18) . Without antigen stimulation, no or only small amounts (5.4 + 8.4 units/ml) of IFN-y were detected in the supernatants. Although some erythrocyte-sensitized donors responded well to erythrocyte lysates, for the test group as a whole this response was not significantly increased over that seen without antigen (7.7 ± 12.7 units/ml; P < 0.4, unpaired t test). In contrast, 15 of the 31 donors released IFN-y significantly above background when incubated with PflS5, suggesting the presence of Pfl55-responsive T cells in half of this group. For the responding donors, the mean IFN-y release was 20.8 ± 12.4 units/ml. Although lower than the release obtained with mitogen, it was significantly increased above background release in the absence of antigen (P < 0.007, unpaired t test) and in line with findings recently made with other P. falciparum antigens and lymphocytes from immune Gambians (22) . Table 3 shows representative results obtained with the cells of 15 donors, all tested with intact antigen and two of the peptides. IFN-y release was not correlated to the anti-PfU55 serum titers. Only donors responding positively to intact Pf1SS released IFN-y with the synthetic peptides. On the average, the response to peptide pla was slightly lower than that to PfUS5 (18.2 ± 17.4 units/ml) but this difference was not statistically significant (P < 0.8, unpaired t test). Only few donors responded above background to p3 (Table 3) . However, available results are too few to permit conclusions regarding possible differences in the response of individual donors to different peptides.
Although the overall number of donors responding to PfUS5 with IFN--y release was similar to that responding in the proliferation assay (15/31 as compared to 13/31, respectively), inspection ofTable 3 shows that these responses were not correlated in individual donors (e.g., the IFN-y+/SIdonors L190, L194, L237 and the IFN-y-/SI + donors L227, L232, L262). This is in accordance with previous results (11) and suggests that the two assays may measure stimulation of primed T cells belonging to different subsets (27, 28) . Whatever the reasons, the results indicate that the IFN-y assay is an important complement to the proliferation assay and should be included in the test panel whenever one wants to determine the degree ofT-cell sensitization in different donor populations.
Concluding Remarks. Taken together the present results show that the C-terminal repeat region of PfU55/RESA, known to contain some of the molecule's immunodominant B-cell epitopes, also includes some of its important T-cell All IFN--y values (units/ml) are corrected by subtracting background release obtained in some donors in the absence of added stimulants. For IFN-y determination, supernatants were collected after 4 days of incubation and for SI determination, cells were harvested on day 5 . Peptides used as stimulants were as follows: pla, Ala-Glu-Glu-Asn-Asp-Glu-Glu-Asn-ValGlu-Glu-Val-(Glu-Glu-Asn-Val)2 and p3, Lys-(Glu-Glu-Asn-Val-Glu-His-Asp-Ala)2. Anti-Pfl55 serum titers were determined by EMIF (4). ND, not done. For other explanations see Table 1 .
epitopes, capable of stimulating T cells to proliferate and/or to release IFN-y. In this respect, Pf155 appears to be different from the circumsporozoite protein of P. falciparum, the immunodominant T-cell domains of which have recently been shown to map to polymorphic regions outside its B-cell immunodominant repeat region (29) . Since the C-terminal repeats of Pf155 appear to be conserved among different P. falciparum strains (7, 10) , the T-cell-activating sequences described in this report appear to be suitable components to be included in a subunit malaria vaccine. They also provide a basis for epidemiological studies relating epitope-specific T-cell responses in vitro to clinical immunity and malaria endemicity. Further work is needed, however, to establish the basis of the apparent Pf155 nonresponsiveness of T cells seen in about half of the donor population tested herein.
